The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
First pivotal Phase 3 trial to show superiority of Keytruda plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC
Manageable safety profile and encouraging antitumor activity observed for MK-1084 in KANDLELIT-001, both as a monotherapy and in studied combinations
The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
Subscribe To Our Newsletter & Stay Updated
